Anti-CGRP Antibodies Have Changed the Migraine Prevention Paradigm After 35 Years of Research
Monoclonal antibodies targeting CGRP or its receptor represent the first migraine-specific preventive treatments, developed from 35 years of translational research linking CGRP to migraine pathophysiology.
Quick Facts
What This Study Found
CGRP/receptor-targeting monoclonal antibodies represent a paradigm shift from repurposed treatments to migraine-specific prevention, with strong clinical trial evidence supporting their efficacy and favorable safety profiles.
Key Numbers
50% responder rate advantage: 21.4% episodic, 17.4% chronic; NNT 4-5 episodic; 4 monoclonal antibodies reviewed
How They Did This
Review of translational research history, clinical trial data, and clinical experience with CGRP-blocking monoclonal antibodies and gepants for migraine prevention.
Why This Research Matters
Migraine affects over 1 billion people worldwide and was previously treated with drugs designed for other conditions. These antibodies are the first treatments designed specifically for migraine biology.
The Bigger Picture
The CGRP antibody story represents one of the most successful examples of bench-to-bedside translational medicine, where basic neuropeptide research led directly to a new class of targeted therapeutics.
What This Study Doesn't Tell Us
Review format. Long-term safety data still accumulating. Cost remains a barrier for many patients. Not all migraine patients respond to anti-CGRP therapy. Head-to-head comparisons between different antibodies are limited.
Questions This Raises
- ?What characterizes patients who respond well versus poorly to anti-CGRP antibodies?
- ?Will oral CGRP receptor antagonists (gepants) reduce the need for injectable antibodies?
- ?Are there long-term consequences of sustained CGRP blockade?
Trust & Context
- Key Stat:
- 35 years to clinical success CGRP antibodies represent 35 years of translational research from neuropeptide discovery to migraine-specific prevention
- Evidence Grade:
- Strong — review of large-scale clinical trial programs for multiple approved antibodies with consistent positive results.
- Study Age:
- Published in 2020; since then, additional CGRP-targeting therapies including oral gepants have expanded treatment options.
- Original Title:
- Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
- Published In:
- Revue neurologique, 176(10), 788-803 (2020)
- Authors:
- Schoenen, J, Manise, M, Nonis, R, Gérard, P, Timmermans, G
- Database ID:
- RPEP-05116
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How are CGRP antibodies different from triptans?
Triptans treat migraine attacks after they start (acute treatment). CGRP antibodies prevent attacks from occurring (preventive treatment) with monthly or quarterly injections, reducing the frequency and severity of migraines.
What makes these the first migraine-specific treatments?
Previous migraine preventives (beta-blockers, antidepressants, anticonvulsants) were developed for other conditions and happened to help migraines. CGRP antibodies were designed specifically to target the CGRP neuropeptide pathway involved in migraine.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05116APA
Schoenen, J; Manise, M; Nonis, R; Gérard, P; Timmermans, G. (2020). Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.. Revue neurologique, 176(10), 788-803. https://doi.org/10.1016/j.neurol.2020.04.027
MLA
Schoenen, J, et al. "Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.." Revue neurologique, 2020. https://doi.org/10.1016/j.neurol.2020.04.027
RethinkPeptides
RethinkPeptides Research Database. "Monoclonal antibodies blocking CGRP transmission: An update ..." RPEP-05116. Retrieved from https://rethinkpeptides.com/research/schoenen-2020-monoclonal-antibodies-blocking-cgrp
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.